An analyst from Anand Rathi said that BHEL is encountering strong resistance in the Rs 265–270 zone, which coincides with its ...

Glenmark’s outlicensing deal with AbbVie for a novel drug for blood cancer under development sets a new course for the ...

A warning letter is a serious communication from the USFDA that signifies a potential risk to public health or safety due to ...

By Kashish Tandon (Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after ...

With the stock currently trading at Rs 2,225.80, Glenmark Pharma has shown a positive movement of 2.05% in today's session.

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

Glenmark Pharmaceuticals receives FDA warning letter for Indore facility, commits to resolving compliance issues promptly.

With a $2-billion cancer drug deal in its pocket, Glenmark’s licensing agreement with AbbVie not only unlocks a potential ...

Glenmark Pharmaceuticals' shares surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

HSBC and Axis Capital are more bullish on its transformative impact and future growth prospects for Glenmark, while Nuvama ...

Glenmark Pharma share price today: Shares of Glenmark Pharma surged 10 per cent, recording a 52-week high of ₹2,094.40 on ...